~~Table~~SECURITIES ofAND ~~Contents~~EXCHANGE COMMISSION Washington, D.C. 20549

~~SECURITIES~~FORM ~~AND EXCHANGE~~8-K ~~COMMISSION~~ ~~Washington, D.C. 20549~~

~~FORM~~CURRENT ~~8-K~~REPORT

~~CURRENT~~PURSUANT ~~REPORT~~TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~Date TOof ~~SECTION~~Report ~~13 OR 15~~(~~d) OF THE~~Date ~~SECURITIES~~of ~~EXCHANGE~~earliest ~~ACT~~event OFreported): ~~1934~~September 23, 2003

~~Date~~BioReliance ~~of Report~~ Corporation (~~Date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):~~specified ~~August 12,~~in ~~2003~~charter)

~~BioReliance Corporation~~Delaware (~~Exact~~State ~~name~~or ofother ~~registrant~~jurisdiction asof ~~specified in charter~~incorporation)

Delaware (State or other jurisdiction of incorporation)


0-22879		52-1541583
(Commission File Number)		(IRS Employer Identification No.)

14920 Broschart Road		20850
Rockville, Maryland		(Zip Code)
(Address of principal executive offices)

0-22879 (Commission File Number)		52-1541583 (IRS Employer Identification No.)
14920 Broschart Road Rockville, Maryland (Address of principal executive offices)		20850 (Zip Code)

Registrant’s telephone number, including area code: (301) 738-1000

~~Registrant’s~~Not ~~telephone~~Applicable (Former ~~number~~name or former address, ~~including~~if ~~area~~changed ~~code:~~since ~~(301~~last report) ~~738-1000~~

~~Not~~Item 2. ~~Applicable (Former~~Acquisition ~~name~~ or ~~former~~Disposition ~~address,~~of ~~if changed since last report)~~Assets

~~TABLE~~Acquisition OFof ~~CONTENTS~~Q-One Biotech Group Ltd.

	Item 5. Other Events
	Item 7. Financial Statements and Exhibits
SIGNATURE
EXHIBIT INDEX
Exhibit 99.1

On September 23, 2003, BioReliance Corporation (the “Company”) completed the acquisition of Q-One Biotech Group Ltd., a privately-held company based in Glasgow, Scotland (“Q-One Biotech”) pursuant to (i) a Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Q-One Biotech) and (ii) a Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Satron Management Services (Technology) Limited) (collectively, the “Share Purchase Agreements”). Q-One Biotech provides safety testing and process validation services and contract manufacturing to the biopharmaceutical industry. Q-One Biotech’s services have included safety testing of biopharmaceuticals, human blood products, vaccines, transgenics and gene therapy products. Q-One Biotech’s primary facilities are located in Glasgow, Scotland and Worcester, Massachusetts.

~~Table~~ Under the terms of ~~Contents~~the Share Purchase Agreements, the Company purchased all of the outstanding capital stock of Q-One Biotech for an aggregate purchase price of approximately £42 million in cash, subject to post-closing adjustments and excluding transaction costs. Pending the determination of the post-closing adjustments £1.5 million has been placed in escrow.

~~Item 5~~ The purchase price was determined in arms-length negotiations between the parties. ~~Other~~ ~~Events~~During such negotiations, the parties considered, among other things, the present condition of the business, operations and assets of Q-One Biotech, Q-One Biotech’s financial condition and the market for Q-One Biotech’s services. Before the consummation of the acquisition, no material relationships existed between the sellers and the Company or any of the Company’s affiliates, any officer or director of the Company, or any associate of any officer or director of the Company.

~~Agreement~~ The toCompany ~~Acquire~~funded ~~Q-One~~the ~~Biotech~~purchase ~~Group~~price ~~Ltd~~of the acquisition, excluding transaction costs, with approximately $48.2 million of borrowings under a new senior secured credit facility with Bank of America, N.A. as administrative agent, security trustee and letter of credit issuer and Banc of America Securities LLC as the sole lead arranger and sole book manager. The Company funded the remainder of the purchase price with approximately $19.7 million of existing cash resources. The new credit facility is described in Item 5 below.

~~Pursuant~~The toforegoing ~~(i) a~~summary ~~Share~~of ~~Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and~~ the ~~sellers named therein (relating to the~~ acquisition ofis ~~shares~~qualified ofin ~~Q-One~~its ~~Biotech~~entirety ~~Group Limited)~~be ~~and~~the ~~(ii) a~~specific ~~Share~~terms ~~Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited~~ and ~~the~~provisions ~~sellers named therein (relating to the acquisition~~ of ~~shares of Satron Management Services (Technology) Limited) (collectively,~~ the “Share Purchase Agreements”), ~~BioReliance~~ ~~Corporation~~which ~~(the “Company”) has agreed to acquire all of the~~are ~~outstanding~~filed ~~shares~~hereto ofas ~~Q-One~~Exhibits ~~Biotech Group Ltd~~2.,1 aand ~~privately-held company based in Glasgow, Scotland (“Q-One”)~~2.2.

~~Under the terms of the Share Purchase Agreements, the Company agreed to purchase all of the outstanding capital stock of Q-One Biotech for an aggregate purchase price of approximately £42~~Item ~~million in cash, subject to adjustments~~5. ~~The~~ ~~Company~~Other ~~expects to fund the purchase price, excluding transaction costs,~~Events ~~with approximately $48 million of borrowings under a new senior secured credit~~ facility, described below, and approximately $20 million of existing cash resources. The transaction is subject to regulatory approval, the closing of the Company’s credit facility and other customary closing conditions. The Company expects to complete the transaction immediately upon regulatory approval, anticipated late in the third quarter of 2003.

ANew ~~copy~~Senior ofSecured ~~the~~Credit ~~joint press release issued by the Company and Q-One, dated~~Facility ~~August 12, 2003, is furnished as Exhibit 99.1 hereto.~~

~~New~~ Pursuant ~~Senior~~to ~~Secured~~a Credit ~~Facility~~Agreement, dated August 12, 2003, among the Company and BioReliance (Glasgow) Ltd. as borrowers, certain subsidiaries of the Company as guarantors, Bank of America, N.A. as administrative agent, security trustee and letter of credit issuer, the lenders party thereto, and Banc of America Securities LLC as the sole lead arranger and sole book manager (the “Credit Agreement”), the Company may borrow up to $60 million for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and to finance the acquisition of Q-One Biotech. The credit facility consists of a $15 million revolving credit facility, a $35 million domestic term loan and a $10 million foreign term loan. The Company borrowed approximately $48.2 million to fund a portion of the purchase price paid in the Q-One Biotech acquisition, including a $3.2 million revolving loan and $45.0 million in term loans. Final amounts due under the revolving credit facility will become due and payable in full on September 30, 2006. The Company is required to make quarterly payments under the term loans beginning on December 31, 2003. Amounts due under the term loans will become due and payable in full on September 30, 2008.

OnThe ~~August 12~~credit facility includes negative covenants including, ~~2003~~among others, those restricting the Company’s ~~entered~~ability ~~into~~to aincur ~~Credit~~liens ~~Agreement~~on ~~among~~its ~~the~~assets, pay ~~Company~~dividends, make investments, and ~~BioReliance~~incur ~~(Glasgow)~~additional ~~Ltd~~indebtedness. asThe ~~borrowers,~~credit facility ~~certain~~also ~~subsidiaries~~contains ofcustomary financial covenants including, among others, those that require the Company asto ~~guarantors,~~maintain ~~Bank~~a ofmaximum ~~America~~leverage ratio, Na minimum fixed charge coverage ratio and a minimum net worth.A. asThe ~~administrative~~credit ~~agent~~facility includes customary events of default including, among other things, the ~~security~~Company’s ~~trustee~~failure ~~and~~to pay the principal or interest of any loan or letter of credit under the credit ~~issuer~~facility, ~~the~~a ~~lenders~~default ~~party~~or ~~thereto,~~event ~~and Banc~~of default of ~~America~~any ~~Securities~~other agreement ~~LLC~~involving asindebtedness, insolvency by the ~~sole~~Company ~~lead~~or ~~arranger~~any of its subsidiaries, and ~~sole~~change ~~book~~in ~~manager~~control of the Company (as defined in the Credit Agreement).

~~Under~~The ~~the~~interest ~~credit~~rate ~~facility,~~on the ~~Company~~credit ~~may~~facility ~~borrow~~is upvariable tobased ~~$60 million~~on ~~for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and to finance~~ the ~~acquisition~~ratio of ~~Q-One.~~ ~~The~~total ~~credit~~funded ~~facility~~debt ~~consists of a $15 million revolving credit facility, a $35 million domestic term loan and a $10 million foreign term loan. Amounts due~~ under the ~~revolving credit~~ facility ~~will~~to ~~become~~the ~~due~~Company’s ~~and payable in full on September 30, 2006~~EBITDA. ~~Amounts~~This ~~due~~ratio ~~under the term loans~~ will be ~~become~~calculated ~~due~~ and ~~payable~~ inreported ~~full~~to onthe ~~September 30,~~lenders ~~2008~~quarterly.

~~The~~Pursuant ~~credit~~to ~~facility~~a ~~includes~~Security ~~negative~~Agreement, ~~covenants~~dated ~~including~~September 22, ~~among others~~2003, ~~those~~ ~~restricting~~by and among the Company’s, ~~ability~~BioReliance toAcquisitions, ~~incur~~Inc., ~~liens~~BioReliance onViral ~~its assets~~Manufacturing, ~~pay~~ ~~dividends~~Inc., ~~make~~BioReliance ~~investments,~~Testing and ~~incur~~Development ~~additional~~LLC, ~~indebtedness.~~BioReliance ~~The~~Manufacturing ~~credit~~LLC, ~~facility~~and ~~also~~Bank ~~contains~~of ~~customary~~America, ~~financial covenants including~~N.A., ~~among~~the ~~others, those~~Company ~~that~~and ~~require~~certain ~~the~~if ~~Company~~its tosubsidiaries ~~maintain~~have granted a ~~maximum~~security ~~leverage~~interest ~~ratio,~~in aall ~~minimum fixed~~personal ~~charge~~property ~~coverage~~currently ~~ratio~~owned ~~and~~or subsequently aacquired ~~minimum~~to ~~net~~Bank ~~worth~~of America, N.A. ~~The~~as ~~credit~~administrative ~~facility~~agent for the ~~includes~~lenders ~~customary~~as ~~events~~security offor ~~default~~their ~~including,~~obligations under the Credit Agreement.

~~Table~~ Pursuant to a Pledge Agreement, dated September 22, 2003, by and among the Company, BioReliance Acquisitions, Inc., BioReliance Viral Manufacturing, Inc., BioReliance Testing and Development LLC, BioReliance Manufacturing LLC, and Bank of ~~Contents~~America, N.A., the Company and certain of its subsidiaries have granted a security

~~among~~interest ~~other~~in ~~things,~~(1) 100% of the ~~Company’s~~capital ~~failure~~stock toof ~~pay~~each ~~the~~domestic ~~principal~~subsidiary orof ~~interest~~the Company, (2) 65% of ~~any~~the ~~loan~~issued orand ~~letter~~outstanding shares of ~~credit~~ ~~under~~capital ~~the~~stock ~~credit~~entitled to ~~facility,~~vote aof ~~default~~each orforeign ~~event~~subsidiary ofand ~~default~~(3) 100% of ~~any~~the ~~other~~issued and outstanding ~~agreement~~Capital ~~involving~~Stock ~~indebtedness,~~not ~~insolvency~~entitled byto ~~the~~vote ~~Company~~of oreach ~~any~~foreign subsidiary of ~~its~~the Company to ~~subsidiaries~~Bank of America, ~~and~~N.A. ~~change~~as inadministrative ~~control~~agent offor the ~~Company~~lenders (as ~~defined~~security infor their obligations under the Credit Agreement).

~~The interest rate on the credit facility is variable based on the ratio of total funded debt under the facility to the Company’s EBITDA~~Item 7. ~~This~~Financial ~~ratio~~Statements ~~will be~~and ~~calculated quarterly.~~Exhibits

~~Item 7.~~ (a) Financial ~~Statements~~statements ~~and~~of a business acquired. It is impracticable for the Company to provide the financial statements for the periods specified in Rule 3-05(b) of Regulation S-X at the time of filing of this Form 8-K. The Company will file the required financial statements as soon as practicable, but not later than sixty days after the date on which this Form 8-K must be filed. (b) Pro forma financial information. It is impracticable for the Company to provide the pro forma financial information required by Article 11 of Regulation S-X at the time of filing of this Form 8-K. The Company will file the required pro forma financial information as soon as practicable, but not later than sixty days after the date on which this Form 8-K must be filed. (c) Exhibits .


	2.1		Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Q-One Biotech)

	2.2		Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Satron Management Services (Technology) Limited)

	10.1		Credit Agreement, dated August 12, 2003, among BioReliance Corporation and BioReliance (Glasgow) Ltd., as Borrowers, the subsidiaries of BioReliance Corporation identified therein, as Guarantors, Bank of America, N.A. as Administrative Agent, Security Trustee and L/C issuer, the Lenders party thereto and Banc of America Securities LLC as the Sole Lead Arranger and Sole Book Manager.

	10.2		Amendment No. 1 and Consent (of the Credit Agreement), dated September 22, 2003, by and among BioReliance Corporation,

			BioReliance (Glasgow) Ltd., the Guarantors and Lenders party thereto and Bank of America, N.A., as Administrative Agent.

	10.3		Form of Revolving Note, dated September 22, 2003, by BioReliance Corporation.

	10.4		Form of Term Note, dated September 22, 2003, by BioReliance Corporation/BioReliance (Glasgow), Ltd.

	10.5		Security Agreement, dated September 22, 2003, by and among BioReliance Corporation, BioReliance Viral Manufacturing, Inc., BioReliance Manufacturing LLC, BioReliance Testing and Development LLC, BioReliance Acquisitions, Inc. and Bank of America, N.A., as Administrative Agent.

	10.6		Pledge Agreement, dated September 22, 2003, by and among BioReliance Corporation, BioReliance Viral Manufacturing, Inc., BioReliance Manufacturing LLC, BioReliance Testing and Development LLC, BioReliance Acquisitions, Inc. and Bank of America, N.A., as Administrative Agent.

~~Forward-Looking Statements~~SIGNATURE

~~Certain~~Pursuant ~~statements~~to ~~made in this Current Report on Form 8-K are “forward-looking statements” within~~ the ~~meaning~~requirements of the ~~Private~~ Securities ~~Litigation~~Exchange ~~Reform~~ Act of ~~1995. Forward-looking statements include~~1934, ~~without limitation, any statement~~as ~~that may predict~~amended, ~~forecast, indicate, or imply future results, performance, or achievements, and may contain~~ the ~~words~~Registrant ~~“believe,”~~has ~~“anticipate,”~~caused ~~“confident,” “expect,”~~this ~~“estimate,”~~report ~~“project,” “will be,” “will continue,” “will likely result,” or similar words or phrases. Comments such as those with respect~~ to ~~(1) the~~ ~~likelihood that the acquisition by BioReliance of Q-One Biotech will close, (2) the amount and timing of synergies that may~~ be ~~achieved~~signed ~~in connection with the acquisition, (3) BioReliance’s ability to effectively and efficiently integrate the operations of Q-One Biotech, and (4) the effect of the transaction~~ on ~~BioReliance’s~~its ~~earnings~~behalf per share constitute forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from the forward-looking statements. Factors that could cause actual results to differ include the possibility that the acquisition will not close, the failure of BioReliance to retain key employees, the failure of BioReliance to effectively manage the cost of integrating the operations of Q-One Biotech, general economic conditions, and the size and growth of the overall markets for biopharmaceuticals, including the amounts spent on research and development by ~~biotechnology and~~ ~~pharmaceutical companies. In addition, risks and uncertainties are detailed from time to time in reports filed by BioReliance with~~ the ~~Securities and Exchange Commission~~undersigned, ~~including~~thereunto induly ~~its Forms 10-K and 10-Q~~authorized. ~~Given these risks~~ ~~and uncertainties, investors should not place undue reliance on forward-looking~~ ~~statements as a prediction of actual results. BioReliance undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements.~~

~~Table~~BIORELIANCE ofCORPORATION ~~Contents~~By: /s/ John L. Coker John L. Coker Senior Vice President, Finance and Administration and Chief Financial Officer

Date: October 8, 2003

~~SIGNATURE~~EXHIBIT INDEX

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	2.1		Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Q-One Biotech)

	2.2		Share Purchase Agreement, dated August 12, 2003, among BioReliance Corporation, BioReliance (Glasgow) Limited and the sellers named therein (relating to the acquisition of shares of Satron Management Services (Technology) Limited)

	10.1		Credit Agreement, dated August 12, 2003, among BioReliance Corporation and BioReliance (Glasgow) Ltd., as Borrowers, the subsidiaries of BioReliance Corporation identified therein, as Guarantors, Bank of America, N.A. as Administrative Agent, Security Trustee and L/C issuer, the Lenders party thereto and Banc of America Securities LLC as the Sole Lead Arranger and Sole Book Manager.

	10.2		Amendment No. 1 and Consent (of the Credit Agreement), dated September 22, 2003, by and among BioReliance Corporation, BioReliance (Glasgow) Ltd., the Guarantors and Lenders party thereto and Bank of America, N.A., as Administrative Agent.

	10.3		Form of Revolving Note, dated September 22, 2003, by BioReliance Corporation.

	10.4		Form of Term Note, dated September 22, 2003, by BioReliance Corporation/BioReliance (Glasgow), Ltd.

	10.5		Security Agreement, dated September 22, 2003, by and among BioReliance Corporation, BioReliance Viral Manufacturing, Inc., BioReliance Manufacturing LLC, BioReliance Testing and Development LLC, BioReliance Acquisitions, Inc. and Bank of America, N.A., as Administrative Agent.

	10.6		Pledge Agreement, dated September 22, 2003, by and among BioReliance Corporation, BioReliance Viral Manufacturing, Inc., BioReliance Manufacturing LLC, BioReliance Testing and Development LLC, BioReliance Acquisitions, Inc. and Bank of America, N.A., as Administrative Agent.

	BIORELIANCE CORPORATION
	By: /s/ John L. Coker
	John L. Coker Vice President, Finance and Administration & Chief Financial Officer
Date: August 26, 2003

EXHIBIT INDEX

99.1 Press Release, dated August 12, 2003.

Table of Contents

Table of Contents

Filing Compare · BIORELIANCE CORP